preloader icon

Apex Trader Funding (ATF) - News

Forbion announces first close of its new BioEconomy Fund I: backing biotech-enabled companies aiming to impact the future of our planet

Forbion, a leading European life sciences venture capital firm, announces the first close of its new fund strategy, Forbion BioEconomy Fund I at €75 million. Forbion BioEconomy Fund I leverages Forbion's extensive biotech expertise in human health to also address planetary health challenges, funding companies that create or replace sustainable products across four sectors: Food, Agriculture, Materials and Environmental Technologies. Alex Hoffmann, General Partner, and Joy Faucher, Partner, who joined Forbion last year, will lead this new strategy with support from industry veterans as venture partners and senior advisors. AMSTERDAM, June 20, 2024 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm, announces the first close of its latest fund, Forbion BioEconomy Fund I ("Forbion BioEconomy"), at €75 million. This fund aims to invest in innovative companies leveraging biotechnologies to create sustainable solutions across four sectors: Food, Agriculture, Materials, and Environmental Technologies. Forbion BioEconomy represents a strategic expansion of Forbion's investment scope, leveraging its extensive biotech expertise in the life sciences sector to address some of our planet's most pressing challenges relating to the environment, the growing need for a sustainable supply of food and the rapid depletion of natural resources. With its investments, the fund will back companies that aim to replace unsustainable products with biotechnology, to transform critical and polluting industries that rely on non-renewable resources. In addition to the potential positive impact of these companies, the market for biotech-enabled alternatives represents a significant commercial opportunity, which is estimated at over $2 trillion in the next decade*. Forbion BioEconomy will target companies that have demonstrated proof of concept, typically at Series A and B stages. The fund focuses on scalable, cost-effective, business-to-business solutions that replace incumbent products at price parity or better. Forbion BioEconomy has already worked up a robust pipeline of ...